Collegium Pharmaceutical Inc (COLL):企業の財務・戦略的SWOT分析

◆英語タイトル:Collegium Pharmaceutical Inc (COLL) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH45721FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年3月
◆ページ数:49
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD250 ⇒換算¥27,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥41,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Collegium Pharmaceutical Inc (COLL) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Collegium Pharmaceutical Inc (Collegium) is a specialty pharmaceutical company that focuses on the development and commercialization of innovative products for treating patients suffering from pain. The company develops products based on its DETERx platform technology. DETERx offers extended-release drug delivery, while protecting against common methods of abuse and tampering. Its lead product, Xtampza ER is designed to provide adequate pain control. Collegium’s other products include Nucynta ER for the treatment of chronic pain and neuropathic pain associated with diabetic peripheral neuropathy; and Nucynta IR for the management of acute pain severe enough to require an opioid analgesic. Collegium is headquartered in Stoughton, Massachusetts, the US.

Collegium Pharmaceutical Inc Key Recent Developments

Feb 11,2021: Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
Jan 06,2021: Collegium provides 2021 financial guidance
Nov 05,2020: Collegium reports net income of $11.3 million in the third quarter of 2020
Sep 25,2020: Collegium appoints Rita Balice-Gordon to its Board of Directors
Aug 05,2020: Collegium reports net income of $8.1 million in the second quarter of 2020

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
Collegium Pharmaceutical Inc – Key Facts
Collegium Pharmaceutical Inc – Key Employees
Collegium Pharmaceutical Inc – Key Employee Biographies
Collegium Pharmaceutical Inc – Major Products and Services
Collegium Pharmaceutical Inc – History
Collegium Pharmaceutical Inc – Company Statement
Collegium Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Collegium Pharmaceutical Inc – Business Description
Product Category: Nucynta
Performance
Product Category: Xtampza ER
Performance
R&D Overview
Collegium Pharmaceutical Inc – Corporate Strategy
Collegium Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
Collegium Pharmaceutical Inc – Strengths
Collegium Pharmaceutical Inc – Weaknesses
Collegium Pharmaceutical Inc – Opportunities
Collegium Pharmaceutical Inc – Threats
Collegium Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Feb 11, 2021: Collegium to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and Provide Corporate Update
Jan 06, 2021: Collegium provides 2021 financial guidance
Nov 05, 2020: Collegium reports net income of $11.3 million in the third quarter of 2020
Sep 25, 2020: Collegium appoints Rita Balice-Gordon to its Board of Directors
Aug 05, 2020: Collegium reports net income of $8.1 million in the second quarter of 2020
Jul 08, 2020: Collegium Pharmaceutical announces appointment of board of directors
May 07, 2020: Collegium reports first quarter 2020 profitability
Feb 27, 2020: Collegium reports full-year 2019 revenue of $296.7 million
Feb 10, 2020: Collegium Pharmaceutical announces Proposed Convertible Senior Notes Offering
Feb 07, 2020: Assertio to divest US rights to Nucynta to Collegium for $375m
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
Collegium Pharmaceutical Inc, Key Facts
Collegium Pharmaceutical Inc, Key Employees
Collegium Pharmaceutical Inc, Key Employee Biographies
Collegium Pharmaceutical Inc, Major Products and Services
Collegium Pharmaceutical Inc, History
Collegium Pharmaceutical Inc, Subsidiaries
Collegium Pharmaceutical Inc, Key Competitors
Collegium Pharmaceutical Inc, Ratios based on current share price
Collegium Pharmaceutical Inc, Annual Ratios
Collegium Pharmaceutical Inc, Annual Ratios (Cont...1)
Collegium Pharmaceutical Inc, Annual Ratios (Cont...2)
Collegium Pharmaceutical Inc, Interim Ratios
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Collegium Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Collegium Pharmaceutical Inc (COLL):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Micell Technologies Inc:医療機器:M&Aディール及び事業提携情報
    Summary Micell Technologies Inc (Micell) is a medical device company that develops drug delivery systems for the treatment of cardiovascular diseases. The company provides product such as MiStent sirolimus eluting absorbable polymer coronary stent system, a drug-eluting stent that is designed to opt …
  • Morinaga & Co., Ltd. (2201):企業の財務・戦略的SWOT分析
    Morinaga & Co., Ltd. (2201) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • Dah Chong Hong Holdings Ltd (1828):企業の財務・戦略的SWOT分析
    Dah Chong Hong Holdings Ltd (1828) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Gartner, Inc.:企業の戦略・SWOT・財務情報
    Gartner, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gartner, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Anpario Plc (ANP):企業の財務・戦略的SWOT分析
    Summary Anpario Plc (Anpario), formerly Kiotech International Plc is a producer and distributor of natural feed additives for animal health, hygiene and nutrition. The company develops products for poultry, pig, ruminant and animal feed markets that include acidifiers, essential oils, enzymes, pelle …
  • G&K Services LLC:戦略・SWOT・企業財務分析
    G&K Services LLC - Strategy, SWOT and Corporate Finance Report Summary G&K Services LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Lava Therapeutics BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Lava Therapeutics BV (Lava Therapeutics) is a biotechnology company which develops immune oncology biopharmaceuticals products. Its proprietary V?9Vd2 T-cell engager candidates bind to the conserved (monomorphic) T-cell receptor of V?9Vd2 T-cells which exhibit potent cytotoxicity, interferon …
  • Edesa Biotech Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Edesa Biotech Inc (Edesa Biotech) is clinical-stage pharmaceutical company that endeavors to develop late stage prescription drugs for dermatological and anorectal indications. It strives to develop safe and effective alternatives to steroids. The company’s product pipeline includes EB01, a …
  • Coloplast AS (COLO B):医療機器:M&Aディール及び事業提携情報
    Summary Coloplast A/S (Coloplast) is a medical device company that offers products and services for ostomy care, urology care, continence care, and skin and wound care. Its major products include ostomy bags; urisheaths; urine bags; catheters; anal irrigation systems; vaginal sling products; advance …
  • EnBW Energie Baden-Wurttemberg AG (EBK):企業の財務・戦略的SWOT分析
    EnBW Energie Baden-Wurttemberg AG (EBK) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Zynerba Pharmaceuticals Inc (ZYNE):企業の財務・戦略的SWOT分析
    Summary Zynerba Pharmaceuticals Inc (Zynerba Pharmaceuticals), formerly AllTranz Inc, is a developer of next-generation synthetic cannabinoid therapeutics. The company provides pipeline product candidates such as ZYN002 and ZYN001. Its ZYN002 is a synthetic CBD, a non-euphoric cannabinoid, formulate …
  • Primearth EV Energy Co Ltd:企業の戦略的SWOT分析
    Primearth EV Energy Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • The Lubrizol Corp:企業の戦略的SWOT分析
    The Lubrizol Corp - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • Kallpa Generacion SA:企業の戦略的SWOT分析
    Kallpa Generacion SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Global Tungsten & Powders Corp.:企業の戦略・SWOT・財務分析
    Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report Summary Global Tungsten & Powders Corp. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Bioverativ Inc (BIVV):医療機器:M&Aディール及び事業提携情報
    Summary Bioverativ Inc (Bioverativ) is a biotechnology company that discovers, develops, and markets therapeutics for the treatment of hemophilia, and rare blood disorders. Its product portfolio includes Eloctate, which comprises recombinant antihemophilic factor engineered using Fc fusion technolog …
  • New Brunswick Power Corporation:企業の戦略的SWOT分析
    New Brunswick Power Corporation - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • Thermo Fisher Scientific Inc (TMO):企業の財務・戦略的SWOT分析
    Thermo Fisher Scientific Inc (TMO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Lloyds Banking Group Plc:企業の戦略・SWOT・財務情報
    Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report Summary Lloyds Banking Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Little Caesar Enterprises Inc:企業の戦略・SWOT・財務分析
    Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report Summary Little Caesar Enterprises Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆